danger
cytokin
storm
occur
sar
involv
immun
disord
mani
aspect
pathogenet
mechan
remain
obscur
sinc
outbreak
deepli
reveal
interact
host
sarscov
base
basic
structur
featur
pathogenassoci
molecular
pattern
creat
new
bioinformat
method
search
potenti
pathogen
molecul
identifi
set
sarscov
specif
gurich
ssrna
fragment
highdens
distribut
genom
vitro
experi
result
show
repres
sarscov
ssrna
power
immunostimulatori
activ
induc
consider
level
proinflammatori
cytokin
tnfa
releas
via
almost
higher
strong
stimulatori
found
previous
viru
moreov
sarscov
ssrna
abl
caus
acut
lung
injuri
mice
high
mortal
rate
vivo
experi
suggest
sarscov
specif
gurich
ssrna
play
import
role
cytokin
storm
associ
dysregul
innat
immun
studi
present
new
evid
immunopatholog
damag
caus
overact
inflamm
sarscov
infect
also
provid
use
clue
new
therapeut
strategi
sar
coronaviru
cov
novel
etiolog
agent
result
atyp
pneumonia
follow
sever
acut
respiratori
syndrom
sar
whole
genom
sequenc
sar
cov
protein
e
n
identifi
structur
function
associ
evas
virul
immun
studi
great
detail
although
much
learn
sinc
outbreak
mani
aspect
pathogenesi
diseas
remain
obscur
viral
interact
host
immun
system
alway
play
central
role
outcom
infect
cytokin
storm
observ
rapid
cours
sar
proinflammatori
cytokin
tnfa
etc
upregul
clinic
serum
cultur
supernat
infer
overact
innat
immun
respons
contribut
virusinduc
immun
patholog
result
acut
lung
injuri
sar
patient
therefor
detail
knowledg
virus
interact
host
innat
immun
system
import
understand
molecular
mechan
pathogenesi
progress
diseas
viru
invas
host
tolllik
receptor
tlr
abl
recogn
differ
pathogenassoci
molecular
pattern
pamp
trigger
innat
immun
respons
recent
spike
protein
propos
recogn
provok
proinflammatori
cytokin
releas
howev
littl
known
role
singlestrand
rna
ssrna
sarscov
kind
potenti
pamp
sinc
gu
guanosin
uridin
rich
region
identifi
natur
agonist
attract
immun
stimulatori
ssrna
exist
kb
length
singlestrand
sarscov
rna
genom
relev
immun
effect
still
unrev
studi
attempt
make
comprehens
investig
sar
gurich
ssrna
sarscov
rna
genom
bioinformat
scan
techniqu
evalu
effect
host
innat
immun
respons
order
reveal
detail
immunopathogenet
mechan
phosphothioateprotect
ssrna
synthes
idt
inc
ia
usa
includ
region
nt
genom
nt
sarscov
genom
gug
nt
sarscov
genom
ua
altern
dotap
liposom
transfect
reagent
n
propyl
n
n
ntrimethylammonium
methylsulf
roch
inc
liposom
transfect
reagent
use
complex
ssrna
addit
cell
cultur
dotapssrna
mixtur
prepar
accord
follow
procedur
ssrna
dilut
hb
hepsbuff
salin
concentr
mgml
dotap
dilut
hb
ratio
dilut
ssrna
dotap
mix
ratio
addit
purchas
invivogen
san
diego
usa
agonist
mous
macrophagelik
cell
line
american
type
cultur
collect
fed
dmem
medium
gibco
usa
human
acut
monocyt
leukemia
cell
line
american
type
cultur
collect
fed
gibco
usa
human
pbmc
isol
normal
human
peripher
blood
densiti
gradient
centrifug
lympholyteh
medium
cedarlan
laboratori
ltd
canada
resuspend
rpmi
addit
cultur
media
supplement
vv
lowendotoxin
fetal
calf
serum
fc
hyclon
usa
iu
ml
penicillin
gml
streptomycin
well
c
co
humidifi
incub
live
cell
dilut
pb
mm
ph
trypan
blue
count
hemocytomet
prepar
cell
resuspend
ml
ml
cultur
media
plate
addit
tlr
agonist
h
cultur
need
adher
cell
cell
group
consist
fourwel
repeat
sampl
group
treat
final
concentr
mgml
denot
posit
control
stimul
treat
mgml
fakerna
neg
control
experi
group
treat
respect
mgml
differ
gurich
ssrna
independ
stimul
compar
analysi
immunostimulatori
activ
perform
respect
concentr
gradient
mgml
cytokin
elisa
tnfa
ifna
group
cultur
c
co
humidifi
incub
supernat
well
collect
h
cultur
measur
tnfa
level
collect
h
cultur
measur
ifna
level
cytokin
detect
enzymelink
immunosorb
assay
elisa
accord
manufactur
protocol
relev
elisa
kit
elisa
kit
use
studi
includ
antimous
antihuman
tnfa
elisa
kit
ebiosci
inc
usa
elisa
kit
boster
inc
china
ifna
elisa
kit
mabtech
inc
usa
cytokin
measur
nm
wavelength
varioskan
flash
spectral
scan
multimod
reader
thermo
scientif
usa
final
one
repres
experi
least
two
independ
experi
would
shown
result
knockdown
sirna
templat
design
rnai
design
invitrogen
inc
base
mrna
sequenc
genbank
access
synthes
invitrogen
inc
preliminari
test
select
best
one
gene
knockdown
three
candid
templat
aauaguguaaggccucaaggaccug
aagaggaacuauuugcauaacucug
accord
standard
sirna
transfect
protocol
provid
invitrogen
inc
sirna
pmolml
transfect
cell
well
plate
cell
confluent
well
h
cultur
well
replac
fresh
normal
growth
medium
meanwhil
experi
group
respect
treat
mgml
tnfa
level
detect
elisa
anoth
h
cultur
adult
male
kunm
mice
ae
g
obtain
anim
center
third
militari
medic
univers
chongq
china
approv
anim
care
use
committe
mice
inject
mg
kg
dgaln
via
tail
vein
one
hour
later
mice
randomli
divid
two
group
n
mice
control
group
took
tail
vein
inject
ml
hb
dotap
mixtur
mice
treatment
group
took
tail
vein
inject
ml
hb
dotap
mix
sarscov
dose
mgkg
bodi
weight
activ
mortal
mice
record
everi
h
first
day
everi
h
last
day
experi
lung
tissu
die
mice
treatment
group
healthi
mice
control
group
cut
fix
paraformaldehyd
least
h
embed
paraffin
deparaffin
dehydr
lung
cut
section
stain
hematoxylin
eosin
smith
score
done
lung
tissu
meanwhil
parallel
experi
cytokin
detect
elisa
mice
treat
h
gurich
ssrna
fragment
detect
scan
whole
genom
sequenc
sar
cov
access
number
access
number
use
inhous
perl
program
base
heil
descript
gurich
motif
gurich
sampl
sequenc
screen
met
threshold
gu
ug
pair
content
least
one
gugu
ugug
motif
contain
everi
scan
window
length
base
moreov
sequenc
similar
check
blast
program
ncbi
tool
data
express
mean
ae
standard
error
compar
studi
mean
carri
use
ttest
analysi
statist
signific
p
valu
graphic
figur
drawn
microsoft
excel
comprehens
gurich
fragment
search
perform
inhous
bioinformat
tool
whole
genom
sequenc
first
natur
gurich
ssrna
identifi
genom
whole
genom
sarscovand
scan
order
make
compar
analysi
total
gurich
ssrna
fragment
found
locat
region
singl
strand
sar
cov
genom
contrast
gurich
ssrna
fragment
found
locat
region
genom
among
previou
detect
well
interestingli
rel
full
length
genom
sarscov
kb
kb
sarscov
twentyfold
higher
distribut
densiti
gurich
fragment
therefor
obviou
gurich
ssrna
fragment
sarscov
much
chanc
contact
host
immun
system
base
data
set
repres
gurich
ssrna
fragment
sarscov
select
follow
function
examin
firstli
similar
analysi
show
gener
similar
sequenc
nucleotid
sequenc
databas
match
suggest
ssrna
character
sarscov
investig
immunolog
role
sarscov
ssrna
follow
section
observ
immun
charact
sever
aspect
vitro
vivo
experi
includ
recognit
stimulatori
activ
immunopatholog
damag
immun
effect
sarscov
specif
ssrna
mediat
observ
upon
cell
express
result
show
gurich
ssrna
includ
induc
significantli
tnfa
releas
contrast
dotap
control
group
p
valu
ua
altern
p
valu
fig
lost
stimulatori
abil
reflect
gurich
motif
core
structur
recognit
interestingli
led
twofold
tnfa
releas
led
higher
tnfa
level
p
valu
howev
product
ifna
detect
seem
like
earli
nfkb
activ
took
place
signal
pathway
meanwhil
knockdown
sirna
transfect
rate
tnfa
level
significantli
decreas
fig
taken
togeth
suggest
sarscov
gurich
higher
stimulatori
perform
specif
earli
nfkb
activ
recognit
hand
immun
effect
sarscov
specif
ssrna
observ
upon
cell
express
data
show
variou
cytokin
detect
ssrna
stimul
includ
tnfa
ifna
unlik
strong
immun
activ
sarscov
led
much
higher
level
tnfa
respect
sarscov
p
valu
reflect
differ
recognit
capabl
ssrna
structur
although
mainli
depend
recognit
gurich
motif
comparison
previous
identifi
immunostimulatori
activ
evalu
treatment
sarscov
differ
dose
data
demonstr
gurich
ssrna
stimul
variou
cytokin
releas
dosedepend
manner
fig
ua
altern
lost
stimulatori
activ
supplementari
fig
interestingli
doseeeffect
curv
everi
typic
inflammatori
factor
present
abl
produc
much
stronger
inflammatori
effect
almost
higher
hand
knockdown
product
cytokin
significantli
decreas
fig
testifi
sarscov
power
stimulatori
abil
induc
high
level
tnfa
releas
investig
integr
effect
sarscov
human
pbmc
product
cytokin
measur
elisa
h
stimul
mgml
ssrna
contrast
dotap
control
induc
multipl
proinflammatori
factor
releas
high
level
p
valu
vs
dotap
fig
testifi
sarscov
possess
power
immunostimulatori
activ
immun
cell
blood
impli
excess
proinflammatori
respons
could
occur
viral
particl
swallow
host
immun
cell
expos
gurich
ssrna
fragment
assess
overact
immun
respons
consequ
caus
sarscov
specif
ssrna
vivo
observ
activ
mortal
lung
histopatholog
chang
treat
mice
nontreat
mice
result
show
gener
statu
mice
group
treat
mgkg
decreas
symptom
listless
sluggish
narcolepsi
half
mice
die
within
h
symptom
disappear
gradual
survivor
h
contrast
normal
control
group
fig
histopatholog
chang
lung
tissu
dead
mice
demonstr
pulmonari
edema
infiltr
inflammatori
cell
alveolar
hemorrhag
compani
alveolar
damag
fig
obviou
chang
lung
structur
control
group
fig
smith
patholog
score
treatment
group
ae
significantli
higher
control
group
ae
p
moreov
comparison
control
group
cytokin
significantli
increas
treatment
group
h
attack
fig
experi
testifi
lowdos
sarscov
specif
ssrna
abl
induc
excess
inflammatori
respons
acut
lung
injuri
vivo
lead
high
mortal
rate
great
deal
clinic
experiment
evid
associ
hypercytokinemia
system
immunopatholog
prove
progress
immuneassoci
injuri
result
sever
acut
respiratori
syndrom
especi
hyperinn
immun
character
cytokin
storm
involv
dysregul
seri
proinflammatori
cytokin
viral
infect
therefor
discov
potenti
pathogen
factor
sar
import
understand
interact
host
viru
studi
base
basic
structur
featur
pamp
first
creat
new
bioinformat
method
search
ssrna
fragment
pathogen
molecular
pattern
comprehens
scan
sarscov
genom
set
sarscov
specif
gurich
ssrna
success
figur
distribut
densiti
analysi
display
sarscov
higher
probabl
releas
gurich
ssrna
contact
host
immun
system
contrast
moreov
experiment
data
confirm
gurich
ssrna
sarscov
abl
induc
innat
immun
respons
fig
tnfa
level
chang
knockdown
sirna
transfect
rate
column
group
cell
treat
mml
dotaphb
column
group
cell
treat
mgml
h
column
group
pmolml
sirna
transfect
cell
treat
mgml
h
column
group
cell
treat
mml
dotaphb
column
group
cell
treat
mgml
h
column
group
pmolml
sirna
transfect
cell
treat
mg
ml
h
signal
pathway
especi
sarscov
power
stimulatori
abil
could
induc
consider
product
tnfa
vitro
approxim
higher
stimulatori
found
furthermor
testifi
acut
lung
injuri
occur
murin
model
high
mortal
attack
lowdos
sarscov
ssrna
similar
clinic
patholog
chang
sar
period
sar
outbreak
mani
clinic
investig
show
seri
proinflammatori
cytokin
abnorm
upregul
blood
sampl
sar
patient
instanc
tnfa
gene
updat
acut
sever
case
product
tnfa
higher
normal
mani
earli
sar
patient
similar
report
show
cytokin
inflammatori
cytokin
increas
type
ifn
report
downregul
although
lot
work
focu
sarscov
protein
interpret
phenomena
pathogen
factor
partli
clarifi
till
recent
year
wang
et
al
confirm
spike
protein
one
pamp
abl
provok
proinflammatori
respons
via
signal
pathway
newli
identifi
sarscov
specif
ssrna
abl
induc
variou
proinflammatori
cytokin
releas
high
perform
quit
consist
immunopatholog
featur
sar
previous
report
doubt
studi
provid
substanti
evid
close
associ
cytokin
storm
unlik
spike
protein
directli
contact
surfac
host
immun
cell
earli
viral
evas
gurich
ssrna
must
recogn
depend
sarscov
replic
manner
stronger
proinflammatori
respons
occur
latent
period
except
host
immun
cell
uptak
viral
particl
essenti
condit
intracellular
recogn
gurich
ssrna
fragment
although
pulmonari
alveolar
epithelium
chief
target
sarscov
sarscov
abl
infect
immatur
matur
human
monocytederiv
dc
incomplet
viral
replic
observ
follow
low
express
antivir
cytokin
ifna
ifnb
etc
upregul
proinflammatori
cytokin
tnfa
interestingli
predominantli
express
lung
placenta
spleen
predominantli
express
lung
peripher
blood
leukocyt
factor
may
provid
sarscov
shortcut
trigger
innat
immun
respons
ultim
contribut
develop
immun
patholog
within
lung
hand
although
phylogenet
structur
relat
specif
agonist
trigger
differ
cytokin
induct
profil
agonist
gener
induc
ifnregul
cytokin
agonist
primarili
lead
product
proinflammatori
cytokin
tnfa
studi
cytokin
profil
show
similar
proinflammatori
respons
pathway
ifna
detect
either
recognit
activ
process
induc
sarscov
gurich
ssrna
mainli
depend
signal
pathway
pathway
impli
overinflamm
occur
togeth
dysfunct
antiviru
immun
respons
relat
type
ifn
acut
sever
period
togeth
accumul
new
evid
closer
clinic
truth
dramat
cytokin
storm
inflammatori
respons
sar
patient
conclus
success
identifi
extraordinari
gurich
ssrna
power
immunostimulatori
activ
sarscov
abl
provok
strong
proinflammatori
respons
via
recognit
caus
acut
lung
injuri
lead
death
find
testifi
gurich
ssrna
sarscov
play
key
role
overact
innat
immun
respons
studi
present
new
evid
comprehens
interpret
occurr
cytokin
storm
immun
pathogenet
mechan
behind
sarscov
infect
also
provid
import
clue
new
therapeut
strategi
